ArticleWorld journal of surgical oncology2017
MiR-221, a potential prognostic biomarker for recurrence in papillary thyroid cancer.
Article in World journal of surgical oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Predicting Risk of Lymph Node Metastasis in Papillary Thyroid Cancer Using miRNAs and Clinicopathological Features.Biochemical genetics · 2026Article
- Emerging liquid biopsy markers in thyroid cancer: from isolation technologies to clinical translation.Frontiers in endocrinology · 2026Review
- Preoperative Expression Profiles of miR-146a and miR-221 as Potential Biomarkers for Differentiating Benign from Malignant Thyroid Nodules.International journal of molecular sciences · 2025Article
- MiRNAs in Extracellular Vesicles as Biomarkers in Plasma of Papillary Thyroid Cancer Patients: A Proof-of-Concept Study.Biology · 2024Article
- Review
- Xanthogranuloma of the Sellar Region: A Comprehensive Review of Neuroimaging in a Rare Inflammatory Entity.Journal of personalized medicine · 2022Review
- Expression Profile and Diagnostic Significance of MicroRNAs in Papillary Thyroid Cancer.Cancers · 2022Article
- Identification of an interactome network between lncRNAs and miRNAs in thyroid cancer reveals SPTY2D1-AS1 as a new tumor suppressor.Scientific reports · 2022Article
- Identification of Exosomal microRNAs and Their Targets in Papillary Thyroid Cancer Cells.Biomedicines · 2022Article
- Melatonin promotes apoptosis of thyroid cancer cells via regulating the signaling of microRNA-21 (miR-21) and microRNA-30e (miR-30e).Bioengineered · 2022Article
- The Importance of miRNA in the Diagnosis and Prognosis of Papillary Thyroid Cancer.Journal of clinical medicine · 2021Review
- Review
- Papillary Thyroid Carcinoma Tissue miR-146b, -21, -221, -222, -181b Expression in Relation with Clinicopathological Features.Diagnostics (Basel, Switzerland) · 2021Article
- MicroRNAs in Papillary Thyroid Cancer: What Is New in Diagnosis and Treatment.Frontiers in oncology · 2021Review
- Different stability of miRNAs and endogenous control genes in archival specimens of papillary thyroid carcinoma.Molecular medicine (Cambridge, Mass.) · 2020Article
- Review
- The Prognostic Value of MicroRNAs in Thyroid Cancers-A Systematic Review and Meta-Analysis.Cancers · 2020Article
- Plasma-Derived miRNA-222 as a Candidate Marker for Papillary Thyroid Cancer.International journal of molecular sciences · 2020Article
- MiR-221/222 promote migration and invasion, and inhibit autophagy and apoptosis by modulating ATG10 in aggressive papillary thyroid carcinoma.3 Biotech · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMany studies have reported several transcriptionally deregulated microRNAs (miRNAs) in papillary thyroid cancer (PTC) tissue in comparison with benign thyroid nodules and normal thyroid tissues. However, the correlation between miRNA expressions and PTC recurrence still remains unclear.
methodsThe PTC patients who scheduled to undergo total thyroidectomy by the same surgical team in Ningbo NO.2 Hospital from March 1998 to March 2008 were enrolled in this study. The clinical and pathological characteristics of each patient were recorded in detail. The selected miRNA expressions were detected using quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR). Potential predictive factors for cancer recurrence were evaluated by univariate and multivariate Cox proportional hazard analysis.
resultsA total of 78 patients were enrolled with 49 females at a mean age of 45.8 years. Enrolled patients were divided into two groups: nonrecurrent group (n = 54) and recurrent group (n = 24). The results from the univariate Cox proportional hazard analysis revealed that primary tumor size, TNM stage, extrathyroid extension, miR-221, and miR-222 expressions were significantly associated with PTC recurrence (P < 0.05). The tissue expression of miR-221 was the only independent risk factor for PTC recurrence (HR 1.41; 95%CI 1.14-1.95, P = 0.007) by multiple Cox proportional hazard analysis.
conclusionsThis study identified the potential role of miR-221 as a prognostic biomarker for the recurrence in PTC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.